Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226980
Status:
COMPLETED
Last Update Posted:
2009-04-14
First Post:
2005-09-13
Brief Title:
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RENAL0001 | None | None | None |
| NCT00226980 | None | None | None |